Drug intelligence / Profile preview

rDEN2Δ30-7169

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

rDEN2Δ30-7169 is a live attenuated dengue virus type 2 (DENV-2) vaccine candidate and challenge strain. It was developed by introducing a 30-nucleotide deletion (Δ30) in the 3' untranslated region of DEN-2 Tonga/74 virus, along with a specific mutation (7169) for further attenuation. The strain is derived from the American genotype of DEN-2 viruses, which has been associated with decreased virulence. It has been used in clinical trials both as a vaccine candidate and as a challenge strain to test the efficacy of other dengue vaccines.

Other names: rDEN2 delta 30-7169rDEN-2 delta 30-7169rDEN 2 delta 30-7169DENV-2 challenge virusDENV2 challenge virusDENV 2 challenge virus

Beyond the preview

Go deeper on rDEN2Δ30-7169.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rDEN2Δ30-7169.

Explore the full profile